Peptide LexiconAll compounds

ACE-031 (Ramatercept): The Muscle-Building Receptor Decoy Whose Trial Was Stopped for Nosebleeds

ACE-031, also called ramatercept, is a lab-made fusion protein that soaks up myostatin and related signals that limit muscle growth. It added lean mass in healthy women after one dose, but its trial in boys with Duchenne muscular dystrophy was stopped over nosebleeds and small dilated blood vessels. This entry covers what it is and the four registered studies.

Discontinued investigational drugNot approved anywhereA protein, not a short peptide

Caroline S · Published 2026-11-16

Length

A fusion protein: the outer part of the activin type IIB receptor joined to an antibody Fc tail (Campbell et al. 2017)

Sequence

No short peptide sequence — the extracellular domain of ActRIIB fused to a human IgG1 Fc (described in the trial reports)

Origin

Investigational drug developed for Duchenne muscular dystrophy; four registered studies on ClinicalTrials.gov

Last reviewed

2026-11-16

What is it good for?

ACE-031 has no approved use. It was developed to build muscle in Duchenne muscular dystrophy by trapping myostatin and other signals that hold muscle growth back. One dose added 3.3% lean body mass in healthy post-menopausal women, but the Duchenne trial was stopped because of nosebleeds and small dilated blood vessels, and development did not continue.

Illustration: A clear glass lab bottle with a stopper and faint green liquid on a concrete surface.
Illustration

What it is

ACE-031, also called ramatercept, is a lab-made fusion protein that works as a decoy for the signals that stop muscle from growing. It joins the outer, signal-catching part of the activin receptor type IIB (ActRIIB) to the Fc tail of a human antibody (IgG1). In the bloodstream it binds myostatin "and other negative regulators of muscle mass" before they reach muscle (Attie et al. 2013, PMID 23169607; Campbell et al. 2017, PMID 27462804).

It was developed for Duchenne muscular dystrophy, a genetic disease in which muscle wastes from childhood.

Property Value Source
Type ActRIIB extracellular domain fused to human IgG1 Fc Campbell 2017
Target Myostatin and related ligands Attie 2013; Campbell 2017
Route in trials Injection under the skin Attie 2013; Campbell 2017
Half-life 10–15 days Attie 2013
Registered studies 4 (2 completed, 2 terminated) ClinicalTrials.gov, 2026-11-16

It is not a short peptide. Libraries and vendor shops file ACE-031 with peptides, but a receptor domain fused to an antibody tail is a large protein. The library keeps an entry because readers arrive with the name; the first fact a reader should have is what kind of molecule it is.

What the trials showed

Healthy volunteers. In a double-blind study, 48 healthy post-menopausal women were randomised 3 to 1 to a single injection of ACE-031 (0.02–3 mg/kg) or placebo. At day 29, the 3 mg/kg group showed a 3.3% rise in total lean mass measured by DXA scan and a 5.1% rise in thigh muscle volume measured by MRI, both statistically significant. Blood markers suggested effects on bone and fat as well. The main side effect named in the abstract was redness at the injection site (Attie et al. 2013).

Boys with Duchenne. The next trial gave ACE-031 under the skin every two to four weeks to boys who could still walk, against placebo, at rising dose levels. Its main aim was safety. It was stopped after the second dose level because of nosebleeds (epistaxis) and telangiectasias — small, dilated blood vessels. The effects on muscle were trends: walking distance in the six-minute walk test held up better than on placebo, lean mass and bone density rose and fat fell, but none of this reached statistical significance. The authors wrote that "non-muscle-related adverse events contributed to the decision to discontinue the study" (Campbell et al. 2017).

Study (ClinicalTrials.gov) People enrolled Status
NCT00755638 — single dose, healthy post-menopausal women 48 Completed
NCT00952887 — healthy post-menopausal women 70 Completed
NCT01099761 — Duchenne 24 Terminated, "based on preliminary safety data"
NCT01239758 — Duchenne extension 11 Terminated, "based on preliminary safety data"

Why the side effects matter for the whole idea. Both trial reports describe ACE-031 as binding myostatin "and related ligands" — other members of the same growth-factor family — and the Duchenne authors called the side effects that stopped the trial non-muscle-related. The library's myostatin inhibitor peptides entry follows that lesson through the rest of the class, and follistatin covers the body's own protein that blocks the same signals.

What is not established: any benefit in people with a muscle disease, any long-term safety record, and anything at all in healthy young adults or athletes — no such study is registered.

Where it stands

ACE-031 has never been approved, and its registered development ended with the two terminated Duchenne studies. It is still sold online as a research chemical labelled a "peptide", which the trial record does not support. MuscleLedger's ACE-031 page covers how it is discussed in gyms. The decision whether a muscle-wasting condition warrants any experimental treatment belongs to a neuromuscular specialist.

Sources opened 2026-11-16: Attie et al., Muscle & Nerve 2013 (PMID 23169607); Campbell et al., Muscle & Nerve 2017 (PMID 27462804); ClinicalTrials.gov API v2 records NCT00755638, NCT00952887, NCT01099761, NCT01239758; PubMed E-utilities counts.

What the research shows

Increases muscle mass after a single dose

Attie et al. 2013, Muscle & Nerve (PMID 23169607): 48 healthy post-menopausal women, randomised 3:1 to ACE-031 or placebo; at 3 mg/kg, lean mass +3.3% and thigh muscle volume +5.1% at day 29

Helps boys with Duchenne muscular dystrophy

Campbell et al. 2017, Muscle & Nerve (PMID 27462804): randomised, placebo-controlled; trends for walking distance and lean mass, not statistically significant; stopped after the second dose level over nosebleeds and telangiectasias

Acts on signals beyond myostatin

Both trial reports: binds myostatin 'and other negative regulators of muscle mass'; the trial authors judged non-muscle side effects decisive

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Regulatory status

Never approved. Both Duchenne studies on ClinicalTrials.gov are marked TERMINATED, "based on preliminary safety data" (NCT01099761, NCT01239758).

Registered studies

Four on ClinicalTrials.gov: two in healthy post-menopausal women (completed, 48 and 70 enrolled) and two in Duchenne (terminated, 24 and 11 enrolled), read 2026-11-16.

Published record

PubMed: 12 records name ACE-031, 2 tagged as randomised trials; 1 uses the name ramatercept (2026-11-16).

Frequently asked questions

What is ACE-031?

An investigational drug, also called ramatercept, made by joining the outer part of a muscle-signal receptor (activin receptor type IIB) to an antibody tail. It works as a decoy that soaks up myostatin and related signals.

Is ACE-031 a peptide?

Not in the usual sense. It is a large fusion protein, far beyond the 50-amino-acid range usually called a peptide. It is sold online under the peptide label, but the trial reports describe a protein.

Did ACE-031 build muscle in people?

In a single-dose study in 48 healthy post-menopausal women, the 3 mg/kg group gained 3.3% lean mass and 5.1% thigh muscle volume by day 29. In boys with Duchenne the gains were trends, not statistically significant.

Why was the ACE-031 trial stopped?

Because of nosebleeds and telangiectasias — small dilated blood vessels — in boys receiving it. The authors wrote that these non-muscle side effects contributed to the decision; both Duchenne studies are listed as terminated on safety data.

Is ACE-031 the same as a myostatin inhibitor peptide?

It is one kind of myostatin blocker, but a receptor-decoy protein rather than a short peptide. Because the receptor also binds other growth-factor signals, it blocks more than myostatin.

Is ACE-031 approved?

No. No regulator has approved it, and its registered development ended with the terminated Duchenne studies.